

Special Issue

Therapeutic Role of Different Enzymes and Inhibitors in Alzheimer's Disease Management

Message from the Guest Editor

Alzheimer's disease (AD) is a predominant neurodegenerative disorder and the principal cause of dementia, affecting a large population worldwide. Therefore, it is fundamental to seek new strategies for AD therapy for the adult population. In this regard, natural and synthetic compounds and peptides are being currently used as therapeutic agents. The different target enzymes, such as acetylcholinesterase (AChE), butyrylcholinesterase (BuChE), monoamine oxidases (MAO), β -secretase, and γ -secretase, are the key enzymes responsible for the development of AD. Currently, natural compounds are being utilized extensively with no or minimum toxicity against these targets for the effective management of AD.

This Special Issue aims to provide an overview of recent studies focused on innovative approaches to treat AD by targeting these enzymes with the help of molecules and drugs as candidates for developing anti-AD drugs.

Original papers, short communications, and review articles in this Special Issue may cover multidisciplinary aspects related to in silico, in vitro, and in vivo experiments.

Guest Editor

Dr. Syed Sayeed Ahmad

Department of Medical Biotechnology, Yeungnam University,
Gyeongsan 38541, Korea

Deadline for manuscript submissions

closed (15 December 2022)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/126973

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)